Transient receptor potential ion channel function in sensory transduction and cellular signaling cascades underlying visceral hypersensitivity

Dafne Balemans,1 Guy E. Boeckxstaens,1 Karel Talavera,2 and Mira M. Wouters1

1Translational Research Center for Gastrointestinal Disorders, University of Leuven, Leuven, Belgium; and 2Laboratory of Ion Channel Research and TRP Research Platform Leuven, Department of Cellular and Molecular Medicine, University of Leuven, Leuven Belgium

Submitted 15 November 2016; accepted in final form 1 April 2017

Visceral (nociceptive) stimuli are sensed by a specialized set of neurons with their cell body in the dorsal root ganglion and free sensory nerve endings in the intestinal wall. These nerve terminals reside in a complex signaling environment where they are subjected to mechanical distortion during distention and a changing milieu of neuroactive signaling molecules that can be modulated by stress, immune cells, and the microbiome (20). The peripheral nerve endings in the gut are equipped with numerous receptors and ion channels that allow them to detect and respond to diverse chemical, mechanical, and thermal stimuli. These visceral signals are then transduced to interneurons in the dorsal horn of the spinal cord that transmit the signal to the brainstem and, if intensely enough, to the cortex for conscious perception. The best studied set of molecular sensors are the TRP...
channels, as they can bind many endogenous lipids and exogenous natural or synthetic compounds (17).

Somatic pain studies repeatedly show that direct activation of TRP channels in sensory nerves triggers protective mechanisms that lead to withdrawal from danger (pain), removal of irritants (itch and cough), and resolution of infection (neurogenic inflammation) (114). These physiologic processes are essential for survival, and are normally under tight control and cease when the initial trigger, for example, inflammation, is removed. However, in the diseased state, longer lasting and sometimes even persistent neuronal hypersensitivity is maintained by TRP channel sensitization (49, 114). This process is characterized by aberrant pain responses to noxious and nonnoxious stimuli, and is a major cause of chronic disorders such as asthma, psoriasis, and FGIDs. The exact mechanisms involved are not fully understood, but it seems that TRP channels act as targets for major downstream effectors of GPCR signaling. Stimulation of GPCR signaling by inflammatory mediators enhances the response to TRP agonists via sensitization, making them very attractive therapeutic targets in various disorders that are characterized by neuronal hypersensitivity.

To date there are 28 TRP genes described in mammals that are grouped into six TRP channel subfamilies: TRPC (canonical), TRPM (melastatin), TRPV (vanilloid), TRPA (ankyrin), TRPM8 (or PKD, polycystin) (130). TRP channels nonselectively conduct cations and, when activated, lead to increased intracellular Na\(^+\) and Ca\(^{2+}\) concentrations, the initiation of neuronal excitation, and a plethora of cellular responses that are relevant to chemo-, thermo-, and/or mechanosensation.

In the gastrointestinal tract, multiple cells express a variety of TRP channels (TRPV1, TRPV3, TRPA1, TRPM2, TRPM5, and TRPM8) that are crucial in tasting seasoned food, thermoregulation of the gut, peristalsis, secretion, mucosal homeostasis, tissue protection, epithelial restitution, controlling of the membrane potential and excitability of neurons, epithelial cells, muscle cells and interstitial cells of Cajal, and visceral sensation (49). Emerging clinical evidence demonstrates aberrant TRP channel expression or function in FGIDs (4, 5, 128), while preclinical models using TRP agonists and transgenic mouse models lacking TRP channels confirm the crucial role of TRP channels in the development and maintenance of colonic afferent hypersensitivity (27, 31, 49, 112). In the following paragraphs, we present an overview of the function and mediators involved in sensitization of TRPV1, TRPV4, TRPA1, TRPM2, and TRPM8 channels in the pathophysiology of VHS as seen in FGIDs.

**TRPV1.** The best characterized and most studied nociceceptor in VHS is TRPV1. TRPV1 is a voltage-gated outwardly rectifying cation channel activated by noxious heat, acidosis (pH < 6) (110), exogenous irritants such as capsaicin (the active component of hot peppers) (25), allyl isothiocyanate (AITC, i.e., mustard oil) (34), and a variety of endogenous lipid compounds, including anandamide (140) and some lipoxigenase metabolites of arachidonic acid (53).

In the gastrointestinal tract, TRPV1 is highly expressed by extrinsic sensory neurons and by intrinsic enteric neurons (7, 8, 121). An overview of clinical and preclinical studies providing evidence for the role of TRPV1 in VHS is presented in Table 1. For example, Akbar et al. (4, 5) showed that, in comparison with healthy individuals, quiescent inflammatory bowel dis-ease (IBD) patients with IBS-like symptoms (4) and IBS patients (5) showed increased numbers of TRPV1-positive nerve fibers that correlate with abdominal pain scores. Others provided rather functional evidence for TRPV1 deregulation, as ingestion of capsaicin capsules caused increased pain responses in patients with diarrhea-predominant IBS and FD patients compared with healthy individuals (41, 46, 68). These findings were corroborated by our group; visceral hypersensitiv-ity (IBS) patients, identified by colorectal balloon distention, experienced more pain during rectal application of capsaicin compared with normosensitive patients and healthy individuals (113). Even though hypersensitive patients reported more pain to rectal capsaicin application, rectal TRPV1 mRNA and protein expression was similar between IBS patients and healthy individuals, suggesting that TRPV1 is sensitized rather than upregulated (113). In a follow-up study, TRPV1 responses to capsaicin were indeed potentiated in rectal submucosal neurons of IBS patients but not in healthy subjects (128). Additionally, murine primary sensory DRG neurons revealed an increased capsaicin-induced intracellular Ca\(^{2+}\) response after overnight incubation with rectal biopsy supernatants of IBS patients but not of healthy subjects, indicating that submucosal biopsies of IBS patients release mediators that can sensitize TRPV1 (128).

The involvement of TRPV1 in VHS has also been demonstrated in various preclinical models of visceral hypersensitivity. For example, increased TRPV1 immunoreactivity was detected in mouse DRG neurons of a post-2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis model and was linked to chemical (capsaicin) and mechanical (colonic distention) VHS (78). Moreover, mice deficient in TRPV1 failed to develop postinflammatory VHS following acute colitis induced by dextran sulfate sodium (DSS) (66). Finally, in a rat stress model of maternal separation, visceral hypersensitivity in adult rats was reversed by a TRPV1 antagonist (112), further underscoring the role of TRPV1 in VHS.

**TRPV4.** The fourth member of the vanilloid subfamily of TRP channels, TRPV4, is a Ca\(^{2+}\)-permeable cation channel that has been detected in both sensory and nonsensory cells. In the gastrointestinal tract, TRPV4 has been reported to be primarily expressed on extrinsic afferent nerve fibers and a variety of nonneuronal cells such as epithelial and endothelial cells. Although TRPV4 was originally identified as a channel activated by hypo-osmotic swelling (69, 105, 127), recent evidence indicates that the channel can be activated by diverse stimuli, including shear stress (38), nonnoxious warm temperatures (44, 124), acidity (108), phorbol esters (both protein kinase C-activating and nonactivating phorbol esters) (38, 122, 131), and downstream metabolites of arachidonic acid (epoxyeicosatrienoic acids) (29, 119, 123).

Accumulating evidence indicates that TRPV4 activation triggers VHS (overview in Table 2). For example, Cenac et al. (29) elegantly demonstrated that the levels of the TRPV4 agonist 5,6-EEET, but not of TRPV1 or TRPA1 agonists, were increased in IBS biopsies compared with controls, and that these increased levels correlated with abdominal pain and bloating scores. Intracolonic infusion of supernatants from IBS biopsies, but not from controls, induced VHS in mice, while knockdown of TRPV4 in mouse primary afferent neurons by siRNA inhibited the hypersensitivity caused by supernatants from IBS biopsies (29). Moreover, polyunsaturated fatty acid
Table 1. Implications of TRPV1 in the pathophysiology of visceral hypersensitivity in FGIDs

<table>
<thead>
<tr>
<th>Tissue (Disease)</th>
<th>Species</th>
<th>Tissue or Cell Type</th>
<th>Technique</th>
<th>Result</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colon (IBD)</td>
<td>Human</td>
<td>Rectosigmoid biopsies</td>
<td>Immunohistochemistry</td>
<td>Increased TRPV1⁺ nerve fibers</td>
<td>4</td>
</tr>
<tr>
<td>Colon (IBS)</td>
<td>Human</td>
<td>Rectosigmoid biopsies</td>
<td>Immunohistochemistry and symptom questionnaires</td>
<td>Increased TRPV1⁺ nerve fibers correlating with abdominal pain</td>
<td>5</td>
</tr>
<tr>
<td>Colon (IBS)</td>
<td>Human</td>
<td>Rectal biopsies</td>
<td>Immunohistochemistry, RT-qPCR</td>
<td>No upregulation of TRPV1</td>
<td>113</td>
</tr>
<tr>
<td>Colon (DSS colitis)</td>
<td>Mice</td>
<td>HEK-293 cells and dorsal root ganglia</td>
<td>Immunohistochemistry, RT-qPCR, Western blot</td>
<td>Upregulation TRPV1 by substance P</td>
<td>66</td>
</tr>
<tr>
<td>Colon (TNBS colitis)</td>
<td>Rats</td>
<td>Dorsal root ganglia</td>
<td>Immunohistochemistry</td>
<td>Increased TRPV1 immunoreactivity</td>
<td>78</td>
</tr>
<tr>
<td>Colon (IBS-D)</td>
<td>Human</td>
<td></td>
<td>Symptom questionnaires</td>
<td>Increased pain sensation to capsaicin capsules</td>
<td>41</td>
</tr>
<tr>
<td>Stomach and small intestine (FD)</td>
<td>Human</td>
<td></td>
<td>Symptom questionnaires</td>
<td>Increased pain sensation to capsaicin capsules</td>
<td>46, 68</td>
</tr>
<tr>
<td>Colon (IBS)</td>
<td>Human</td>
<td></td>
<td>Symptom questionnaires</td>
<td>Rectal capsaicin application induced increased pain perception</td>
<td>113</td>
</tr>
<tr>
<td>R ectum and colon (IBS)</td>
<td>Human and mice</td>
<td>Submucosal neurons (human) and dorsal root ganglia (mouse)</td>
<td>Calcium imaging and symptom questionnaires</td>
<td>Increased TRPV1 sensitivity in IBS mediated by histamine and Hrh1. Symptom reduction after treatment with Hrh1 antagonist</td>
<td>128</td>
</tr>
<tr>
<td>Colon (DSS colitis)</td>
<td>Mice</td>
<td>Serosal afferent nerves</td>
<td>Colorectal distention and afferent nerve recording</td>
<td>TRPV1 deficiency prevents postinflammatory VHS</td>
<td>6</td>
</tr>
<tr>
<td>Colon</td>
<td>Mice</td>
<td></td>
<td>Colorectal distention</td>
<td>Inflammatory mediators sensitize TRPV1 resulting in VHS, an effect lacking in TRPV1 knockout mice</td>
<td>56</td>
</tr>
<tr>
<td>Colon</td>
<td>Mice</td>
<td>Dorsal root ganglia</td>
<td>Patch-clamp</td>
<td>TRPV1 sensitization by 5-HT</td>
<td>106</td>
</tr>
<tr>
<td>Colon</td>
<td>Rat</td>
<td>Dorsal root ganglia</td>
<td>Maternal separation: colorectal distention</td>
<td>VHS after maternal separation reversed by TRPV1 antagonist</td>
<td>112</td>
</tr>
<tr>
<td>Colon</td>
<td>Rat</td>
<td>Dorsal root ganglia</td>
<td>Colorectal distention and patch-clamp</td>
<td>Depletion 5-HT decreases capsaicin response and VHS</td>
<td>92</td>
</tr>
</tbody>
</table>

TRPV, transient receptor potential (vanilloid); FGIDs, functional gastrointestinal disorders; IBD, inflammatory bowel disease; IBS, irritable bowel syndrome; DSS, dextran sulfate sodium; TNBS, 2,4,6-trinitrobenzenesulfonic acid; IBS-D, diarrhea predominant IBS; FD, functional dyspepsia; HEK, human embryonic kidney (cells); RT-qPCR, quantitative reverse transcription PCR; Hrh1, histamine 1 receptor; VHS, visceral hypersensitivity; 5-HT, 5-hydroxytryptamine.

metabolites extracted from IBS biopsies or colons of mice with VHS activated mouse sensory neurons in vitro, an effect that was mediated by TRPV4 activation. Intriguingly, the supernatants of IBS biopsies itself did not contain 5,6-EET, but triggered the production of 5,6-EET by mouse sensory neurons via a mechanism that involved the protease-activated receptor-2 (PAR-2) and cytochrome epoxygenase (29), indicating that sensory neurons themselves produce TRPV4 agonists upon activation by proteases. Moreover, recently it was shown that human serosal nociceptor mechanosensitivity was attenuated by application of the TRPV4 antagonist HC067047, further underscoring the potential role of TRPV4 in VHS (74).

Using live imaging of rectal biopsies, we recently found increased Ca²⁺ responses to TRPV4 agonist GSK1016790A in submucosal neurons of IBS patients compared with healthy controls, an effect that could be mimicked by histamine in submucosal neurons of healthy subjects. As no increased TRPV4 messenger RNA (mRNA) was found, we hypothesize that TRPV4 is rather sensitized than upregulated (11). Also, in patients suffering from acute IBD, TRPV4 mRNA is highly enriched in colonic sensory neurons (21) and in colonic biopsies obtained from patients with Crohn’s disease and ulcerative colitis compared with healthy subjects (36). Data on TRPV4 expression in IBD patients in remission and suffering from VHS are lacking so far.

In addition to the clinical data indicating a potential role for TRPV4 in VHS, various preclinical models already provide functional evidence. Activation of TRPV4 by the TRPV4 agonist 4α-phorbol 12,13-didecanoate (4α-PDD) in colonic projections of DRG neurons induced mechanical VHS in a dose-dependent manner (27). Moreover, mechanosensory responses of colonic serosal and mesenteric fibers were enhanced by the TRPV4 agonist 5,6-EET, and significantly reduced by targeted deletion of TRPV4 or by the TRPV4 antagonist ruthenium red (21). Others showed that intervertebral pretreatment of mice with TRPV4 directed small interfering RNA (siRNA) reduced basal visceral nociception, as well as 4α-PDD agonist-induced hypersensitivity (27). Furthermore, selective blockade of TRPV4 in the TNBS colitis mouse model alleviated colitis and pain associated with acute intestinal inflammation (36). On the basis of these data, TRPV4 seems an important colonic nociceptor that mediates both mechanical and chemical hyperalgesia. Despite these findings, more clinical studies investigating the role of TRPV4 in VHS in IBS, FD, and IBD patients in remission are warranted.

TRPA1. In mammals, TRPA1 is the sole member of the TRPA gene subfamily. TRPA1 is a cold- and mechanosensitive TRP channel activated by cooling to the noxious cold range of temperatures (<17°C) (104). TRPA1 is best known as an irritant sensor and is activated by a wide variety of pungent compounds, such as cinnamaldehyde (12), AITC (57), allicin (15), menthol (59), inflammatory fatty acids, prostaglandin metabolites, and hydrogen peroxide (9, 72). In addition, TRPA1 acts as a sensor of bacterial lipopolysaccharides (77,
In the gastrointestinal tract of mammals, TRPA1 has been shown to be expressed on extrinsic primary afferent nerves as well as in intrinsic enteric neurons (84, 104). Besides neuronal cells, TRPA1 is also highly expressed in nonneuronal 5-hydroxytryptamine-releasing enterochromaffin cells (80), cholecystokinin-releasing endocrine cells (91), and intestinal epithelial cells (63). Recent reports identified TRPA1 as a target for the noxious and inflammatory irritant AITC in peripheral sensory neurons, implicating a functional role in pain and neurogenic inflammation (overview in Table 3). Although the majority of the literature on TRPA1 in VHS is based on preclinical studies, a recent study reported upregulation of TRPA1 mRNA expression in biopsies of active IBD patients but not in quiescent IBD patients (65). This effect on acute pain perception was already described by Meseguer et al. (77) who found that TRPA1 channels mediate acute neurogenic inflammation and pain produced by LPS. Also, in mice, intracolonic administration of a TRPA1 agonist increased the visceromotor response, an effect that was absent in TRPA1 deficient mice (19, 26). Others showed upregulation of TRPA1 expression in colonic DRGs of mice suffering from acute TNBS-induced colitis that led to an enhanced visceromotor response to colorectal distention, an effect that was prevented by intrathecal pretreatment with a TRPA1 antisense oligodeoxynucleotide (134) and TRPA1 blockade (115). In addition, the TRPA1 agonist AITC induced colonic hypersensitivity in a mild DSS colitis model that was prevented by treatment with a TRPA1 antagonist (79).

Besides its role in acute pain perception, preclinical models showed that intracolonic treatment of newborn mouse pups with the TRPA1 agonist AITC triggers a permanent increase in the percentage of TRPA1-positive DRG neurons as well as in intrinsic enteric afferent nerves as well as in intrinsic enteric neurons (84, 104). Besides neuronal cells, TRPA1 is also highly expressed in nonneuronal 5-hydroxytryptamine-releasing enterochromaffin cells (80), cholecystokinin-releasing endocrine cells (91), and intestinal epithelial cells (63). Recent reports identified TRPA1 as a target for the noxious and inflammatory irritant AITC in peripheral sensory neurons, implicating a functional role in pain and neurogenic inflammation (overview in Table 3). Although the majority of the literature on TRPA1 in VHS is based on preclinical studies, a recent study reported upregulation of TRPA1 mRNA expression in biopsies of active IBD patients but not in quiescent IBD patients (65). This effect on acute pain perception was already described by Meseguer et al. (77) who found that TRPA1 channels mediate acute neurogenic inflammation and pain produced by LPS. Also, in mice, intracolonic administration of a TRPA1 agonist increased the visceromotor response, an effect that was absent in TRPA1 deficient mice (19, 26). Others showed upregulation of TRPA1 expression in colonic DRGs of mice suffering from acute TNBS-induced colitis that led to an enhanced visceromotor response to colorectal distention, an effect that was prevented by intrathecal pretreatment with a TRPA1 antisense oligodeoxynucleotide (134) and TRPA1 blockade (115). In addition, the TRPA1 agonist AITC induced colonic hypersensitivity in a mild DSS colitis model that was prevented by treatment with a TRPA1 antagonist (79).
TRPV1 in VHS. Indeed, in sensory neurons, TRPA1 has been shown to act in concert with TRPV1 (see details below). Finally, we recently demonstrated an increased TRPA1 agonist-induced Ca\textsuperscript{2+}/H\textsubscript{1} response in rectal submucosal neurons of IBS patients compared with those of healthy controls (11). Furthermore histamine was able to potentiate TRPA1 responses in submucosal neurons of healthy subjects. Again, TRPA1 mRNA expression was not upregulated in rectal biopsies of IBS patients compared with healthy individuals, suggesting that also TRPA1 is sensitized in IBS (11). Even though these studies are promising, more clinical studies are required to better understand the role of TRPA1 in VHS in FGIDs.

TRPM2. TRPM2 is a heat-sensitive TRP channel that belongs to the melastatin subgroup of the TRP channel superfamily. It can be activated by intracellular ADP ribose and extracellular stimuli such as reactive oxygen species (47, 85, 125). TRPM2 channels are expressed by intrinsic and spinal primary afferent neurons innervating the distal colon in rat (73). Besides neuronal cells, TRPM2 is also expressed in mucosal macrophages and mast cells and contributes to the progression of experimental colitis and food allergy in mice (81, 133).

Several reports show that TRPM2 deficiency has anti-allo-dynnic effects in a wide variety of inflammatory and neuropathic pain mouse models (101), suggesting that TRPM2 may be a new therapeutic target for controlling chronic pain. Furthermore, a recent study found evidence for a role of TRPM2 in visceral nociception and hypersensitivity (73) (overview in Table 4). TRPM2 expression was increased in distal colon of a TNBS colitis rat model, and oral administration of TRPM2 antagonist or TRPM2 deficiency reduced the visceromotor response to noxious colorectal distention in rats. These data suggest that TRPM2 is involved in VHS and may present a novel therapeutic target for VHS triggered by intestinal inflammation. To date clinical studies investigating the role of TRPM2 in visceral pain sensation in FGIDs are completely lacking, but are definitely warranted to establish preclinical evidence.

Table 3. Implications of TRPA1 in the pathophysiology of visceral hypersensitivity in FGIDs

<table>
<thead>
<tr>
<th>Tissue (disease)</th>
<th>Species</th>
<th>Tissue or Cell Type</th>
<th>Technique</th>
<th>Result</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colon (IBD)</td>
<td>Human</td>
<td>Colonic biopsies</td>
<td>Immunohistochemistry and RT-qPCR</td>
<td>Upregulation TRPA1</td>
<td>65</td>
</tr>
<tr>
<td>Colon (mustard oil colitis)</td>
<td>Mice</td>
<td>Colonic tissue</td>
<td>RT-qPCR</td>
<td>Upregulation TRPA1 on colonic afferent nerves</td>
<td>61</td>
</tr>
<tr>
<td>Colon</td>
<td>Mice</td>
<td>Dorsal root ganglia</td>
<td>Immunohistochemistry</td>
<td>Treatment mice pups with TRPA1 agonist increases TRPA1 expression</td>
<td>31</td>
</tr>
<tr>
<td>Colon (TNBS)</td>
<td>Mice</td>
<td>Dorsal root ganglia</td>
<td>Western blot</td>
<td>Upregulation TRPA1</td>
<td>115, 134</td>
</tr>
<tr>
<td>Colon</td>
<td>Rats</td>
<td>Dorsal root ganglia</td>
<td>Calcium imaging</td>
<td>Increased TRPA1 sensitivity in IBS mediated by histamine and Hrh1.</td>
<td>11</td>
</tr>
<tr>
<td>Rectum and colon (IBS)</td>
<td>Human and mice</td>
<td>Submucosal neurons (human) and dorsal root ganglia (mice)</td>
<td>Functional data</td>
<td>Increased TRPA1 sensitivity in IBS mediated by histamine and Hrh1.</td>
<td>11</td>
</tr>
<tr>
<td>Colon</td>
<td>Mice</td>
<td>Submucosal neurons (human) and dorsal root ganglia (mice)</td>
<td>Calcium imaging</td>
<td>Intra-colonic administration of TRPA1 agonists induces VHS, absent in TRPA1 knockout mice</td>
<td>19, 26</td>
</tr>
<tr>
<td>Colon</td>
<td>Mice</td>
<td>Colorectal distention</td>
<td>Treatment mice pups with TRPA1 agonist results in adult VHS</td>
<td>31</td>
<td></td>
</tr>
<tr>
<td>Colon</td>
<td>Mice</td>
<td>Colorectal distention</td>
<td>Intracolic PAR-2 agonist administration induces VHS, absent in TRPA1 knockout mice</td>
<td>26</td>
<td></td>
</tr>
<tr>
<td>Colon</td>
<td>Mice</td>
<td>Serosal and mesenteric afferent nerves</td>
<td>Colorectal distention and afferent nerve recording</td>
<td>Bradykinin increases mechanosensitivity in afferent nerves and VHS, absent in TRPA1 knockout mice</td>
<td>19</td>
</tr>
<tr>
<td>Colon</td>
<td>Mice</td>
<td>Serosal and mesenteric afferent nerves</td>
<td>Afferent nerve recording</td>
<td>No interaction of PAR-2 and TRPM2 in splanchnic afferents</td>
<td>19</td>
</tr>
<tr>
<td>Colon (TNBS and DSS colitis)</td>
<td>Rats and mice</td>
<td>Serosal and mesenteric afferent nerves</td>
<td>Colorectal distention</td>
<td>VHS absent in TRPM2</td>
<td>26, 79, 115, 134</td>
</tr>
</tbody>
</table>

TRPA, transient receptor potential (ankyrin).

Table 4. Implications of TRPM2 in the pathophysiology of visceral hypersensitivity in FGIDs

<table>
<thead>
<tr>
<th>Tissue (Disease)</th>
<th>Species</th>
<th>Tissue or Cell Type</th>
<th>Technique</th>
<th>Result</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colon (TNBS- colitis)</td>
<td>Rat</td>
<td>Distal colon</td>
<td>Immunohistochemistry</td>
<td>Increased TRPM2 expression</td>
<td>73</td>
</tr>
<tr>
<td>Colon (TNBS- colitis)</td>
<td>Rat</td>
<td>Distal colon</td>
<td>Colorectal distention</td>
<td>Treatment with TRPM2 antagonist restores VHS</td>
<td>73</td>
</tr>
</tbody>
</table>

TRPM, transient receptor potential (melastatin).
TRPM8 may be able to convey these different sensory modalities of innocuous cool sensation, nociception, and analgesia. How TRPM8 is expressed by peripheral sensory neurons of visceral organs (48) and may be involved in the development of VHS (overview in Table 5). Although the role of TRPM8 in VHS in FGIDs has hardly been studied yet, preclinical models suggest that activation of TRPM8 results in a diminished visceral pain perception. Transgenic mice deficient for TRPM8 exhibit loss of acute innocuous cold sensation, impaired responses to noxious cold temperatures, and deficits in nocifensive responses to cooling compounds and impaired inflammatory and neuropathic cold allodynia. For example, post-TNBS-induced colonic mechanohypersensitivity was significantly reduced by a mixture of the TRPM8 agonists peppermint and caraway oil (3). Also, pilot clinical trials wherein IBS patients are treated with enteric-coated peppermint oil decreased abdominal pain together with an increase in life quality (23, 62, 76). The mechanism underlying these clinical findings is not fully understood, but one study showed that TRPM8 activation on colonic afferents triggers mechanical desensitization combined with diminished agonist-evoked responses to TRPA1 and TRPV1, indicating that TRPM8 couples to TRPV1 and TRPA1 to inhibit their downstream chemosensory and mechanosensory actions (48). Others propose that TRPM8 exerts anti-inflammatory properties. Pretreatment with the TRPM8 agonist icilin decreased inflammatory cytokines and mucosal damage in a TNBS and DSS experimental colitis model, suggesting an anti-inflammatory role for TRPM8 activation, in part due to an inhibition of neuropeptide release (93). Of note, not all authors confirm these antinociceptive and anti-inflammatory findings, as Hosoya et al. (50) showed increased expression of TRPM8 in the distal colon mucosa of a TNBS and DSS mouse colitis model and treatment with the TRPM8 agonist WS-12 induced increased visceral pain responses compared with controls, which was prevented by pretreatment with a TRPM8 antagonist.

Taken together, depending on the context, TRPM8 functions in innocuous cool sensation, nociception, and analgesia. How TRPM8 may be able to convey these different sensory modalities is still unclear and awaits further investigation.

Mechanisms Underlying Sensitization of TRP Channels in Visceral Hypersensitivity

Given that TRP channels are crucial in the development and maintenance of VHS, it is clear that insight into the mechanisms contributing to persistent TRP channel activation or sensitization is key for the development of novel therapeutic strategies. In general, TRP channels play three distinct cellular roles: 1) TRP channels operate as molecular sensors, that is, primary detectors and transducers of chemical and physical stimuli from the microenvironment; 2) TRP channels act as downstream or secondary transducers of cell activation mediated by GPCRs or ion channel activation; and 3) TRP channels function as ion transport channels, for example, for Ca2+ and Mg2+ responsible for cellular homeostasis. Within primary afferent neurons, translation of signals detected by TRP channels into effector responses is carried out by the local release of neuropeptides from the peripheral fibers of TRP-expressing afferent neurons, which causes changes in local tissue function, and on the other hand, by transmission of the signals to the central nervous system resulting in (nociceptive) sensation.

Long-term deregulation and disease can lead to chronic TRP channel sensitization, thereby triggering VHS. However, the exact mechanisms underlying long-term sensitization of TRP channels in FGIDs are not fully understood. From somatic pain studies and studies in the skin we know that the GPCR-TRP axis plays a central role in TRP sensitization (114). Indeed, GPCRs enable sensory neurons to detect diverse stimulants and inhibitors, including amines (histamine and serotonin), peptides (kinins, tachykinins, and opioids), purines and nucleotides (adenosine and ATP), lipids (prostaglandins), steroids (bile acids), and proteases (serine and cysteine). The capacity of GPCRs to excite primary sensory neurons requires activation of TRP channels, and the activities of many GPCRs converge on a small number of TRP channels that are vitally important for sensory signaling. GPCRs can stimulate TRPs by two general mechanisms: 1) Gα-mediated activation of phospholipases that relieve phosphatidylinositol 4,5-biphosphate (PIP2)-dependent channel inhibition and generate endogenous TRP agonists and 2) stimulation of kinases (protein kinase C, PKA, and tyrosine kinases) that phosphorylate TRPs to in-

Table 5. Implications of TRPM8 in the pathophysiology of visceral hypersensitivity in FGIDs

<table>
<thead>
<tr>
<th>Tissue (Disease)</th>
<th>Species</th>
<th>Tissue or Cell Type</th>
<th>Technique</th>
<th>Result</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colon (IBD, TNBS, and DSS colitis)</td>
<td>Human and mice</td>
<td>Colonic tissue</td>
<td>RT-qPCR</td>
<td>Upregulation TRPM8</td>
<td>93</td>
</tr>
<tr>
<td>Colon (TNBS and DSS colitis)</td>
<td>Mice</td>
<td>Colonic tissue</td>
<td>Immunohistochemistry</td>
<td>Increased TRPM8 expression</td>
<td>50</td>
</tr>
<tr>
<td>Colon (IBS)</td>
<td>Human</td>
<td></td>
<td>Symptom questionnaires</td>
<td>Treatment with TRPM8 agonist decreases IBS symptoms such as abdominal pain and increases quality of life</td>
<td>23, 24, 62, 76</td>
</tr>
<tr>
<td>Colon (TNBS and DSS colitis)</td>
<td>Mice</td>
<td>Serosal and mesenteric afferent nerves</td>
<td>Evaluation of pain-related behavior</td>
<td>Treatment with TRPM8 agonist increases visceral pain sensitivity</td>
<td>50</td>
</tr>
<tr>
<td>Colon (TNBS and DSS colitis)</td>
<td>Mice</td>
<td>Colonic tissue and HEK-293 cells</td>
<td>Aff erent nerve recording</td>
<td>TRPM8 activation desensitizes TRPV1 and TRPA1</td>
<td>48</td>
</tr>
<tr>
<td>Colon (TNBS postinflammatory VHS)</td>
<td>Rats</td>
<td></td>
<td>Calcium imaging</td>
<td>TRPM8 agonists have anti-inflammatory effect and inhibits capsaicin-induced responses</td>
<td>93</td>
</tr>
</tbody>
</table>

AJP-Gastrointest Liver Physiol • doi:10.1152/ajpgi.00401.2016 • www.ajpgi.org
TRPV1 contains numerous phosphorylation sites for serine and threonine protein kinases such as PKA, PKC, CaMK II, and sarcoma (Src) kinase, all of which regulate TRPV1 activity by a dynamic interplay between receptor phosphorylation and dephosphorylation (52). This complex system allows TRPV1 sensitization by various inflammatory mediators and receptors involved in TRP sensitization and VHS.

**TRPV1.** TRPV1 contains numerous phosphorylation sites for serine and threonine protein kinases such as PKA, PKC, CaMK II, and sarcoma (Src) kinase, all of which regulate TRPV1 activity by a dynamic interplay between receptor phosphorylation and dephosphorylation (52). This complex system allows TRPV1 sensitization by various inflammatory mediators and receptors in vitro, ex vivo, and in models of somatic pain (30, 51, 55, 58, 95, 107, 111, 137). For example, TRPV1 is potentiated by bradykinin in a PKC-dependent way (107, 109); by PAR-2 in a phospholipase C example, TRPV1 is potentiated by bradykinin in a PKC-

### Table 6. GPCR signaling-mediated sensitization of TRP channels

<table>
<thead>
<tr>
<th>Receptor (Ligand)</th>
<th>Signaling Mechanism</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRPV1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BK2 (bradykinin)</td>
<td>PKC</td>
<td>107, 109</td>
</tr>
<tr>
<td>PAR-2 (protease)</td>
<td>PLC, PKC, PKA</td>
<td>30</td>
</tr>
<tr>
<td>Hrh1 (histamine)</td>
<td>PLC, PKC</td>
<td>58, 128</td>
</tr>
<tr>
<td>PGR (prostaglandin E2)</td>
<td>PKA</td>
<td>51, 95</td>
</tr>
<tr>
<td>TrkA (NGF)</td>
<td>PI3, Src kinase</td>
<td>55, 137</td>
</tr>
<tr>
<td>5HT1R, 5HT4R (serotonin)</td>
<td>PKA, PKC</td>
<td>106</td>
</tr>
<tr>
<td>TRPV4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PAR-2 (protease)</td>
<td>PKA, PKC</td>
<td>43</td>
</tr>
<tr>
<td>Hrh1 (histamine)</td>
<td>PKC, PLC, PLA2, MAPK</td>
<td>11, 28</td>
</tr>
<tr>
<td>5HT1R (serotonin)</td>
<td>PKC, PLC, PLA2, MAPK</td>
<td>28</td>
</tr>
<tr>
<td>BK2 (bradykinin)</td>
<td>PKC, PLC</td>
<td>35</td>
</tr>
<tr>
<td>TRPA1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BK2 (bradykinin)</td>
<td>PLC, PKA</td>
<td>97, 120</td>
</tr>
<tr>
<td>PAR-2 (protease)</td>
<td>PKA, PKC, PLC, PIP2</td>
<td>30, 32</td>
</tr>
<tr>
<td>Hrh1 (histamine)</td>
<td>–</td>
<td>11</td>
</tr>
<tr>
<td>TRPM5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PGR (prostaglandin E2)</td>
<td>PKA</td>
<td>71</td>
</tr>
<tr>
<td>BK2 (bradykinin)</td>
<td>PKC</td>
<td>88</td>
</tr>
<tr>
<td>5HT1H (serotonin)</td>
<td>PIP2, PIP3</td>
<td>117</td>
</tr>
</tbody>
</table>

GPCR, G protein-coupled receptor.

increase cell surface expression and interactions with adaptor proteins. These mechanisms lead to TRP channel sensitization or activation (114, 118) (overview in Table 6). The net result is that TRP channels can amplify the effects of GPCRs and mediate their contributions to transmission of pain and neurogenic inflammation. Below we review the present knowledge of mediators and receptors involved in TRP sensitization and VHS.

**TRPV1.** TRPV1 contains numerous phosphorylation sites for serine and threonine protein kinases such as PKA, PKC, CaMK II, and sarcoma (Src) kinase, all of which regulate TRPV1 activity by a dynamic interplay between receptor phosphorylation and dephosphorylation (52). This complex system allows TRPV1 sensitization by various inflammatory mediators and receptors in vitro, ex vivo, and in models of somatic pain (30, 51, 55, 58, 95, 107, 109, 111, 137). For example, TRPV1 is potentiated by bradykinin in a PKC-dependent way (107, 109); by PAR-2 in a phospholipase C (PLC), PKA-, and PKC-dependent manner (30); by histamine through activation of the histamine 1 receptor (Hrh1) and PLC and PKC activation (58); by prostaglandin E2 (PGE2) through PKA-dependent phosphorylation (51, 95); by extracellular ATP secreted by damaged cells (111); and by nerve growth factor (NGF) acting on the TrkA receptor, activating a signaling pathway in which PI3 kinase and Src kinase bind and phosphorylate TRPV1 (55, 137).

Recent literature provided evidence that TRPV1 sensitization by GPCR activation may also contribute to aberrant visceral pain perception. In vitro exposure of murine colonic afferents to an acidic inflammatory soup containing bradykinin, serotonin (5-HT), histamine, and PGE2 induced mechanical sensitization, an effect that was not observed in TRPV1 knockout mice (56). In particular, 5-HT exerts TRPV1 sensitizing effects as a preexposure of mouse sensory neurons in lumbosacral DRG neurons receiving colonic input to 5-HT-augmented TRPV1 activation in a 5-HT2- and 5-HT4-dependent manner (106). Downstream signaling required G protein activation and phosphorylation, as intracellularly administered PKA inhibitors and an A kinase anchoring protein inhibitor significantly blocked serotonergic facilitation of TRPV1 function. 5-HT2 receptor-mediated facilitation was also inhibited by a PKC inhibitor, and the authors concluded that the facilitation of TRPV1 by metabotropic 5-HT receptor activation may contribute to hypersensitivity of primary afferent neurons (106). Indeed, Qin et al. (92) also showed that depletion of 5-HT from the colon reduced the excitability of DRG neurons by capsaicin.

We recently demonstrated that TRPV1 responses to capsaicin are potentiated in rectal submucosal neurons of IBS patients compared with those of healthy subjects (128), an effect that was histamine dependent. We showed an increased capsaicin-induced response of sensory DRG neurons after overnight incubation with rectal biopsy supernatants of IBS patients compared with healthy subjects. As this effect was also mediated via activation of the Hrh1 (128), we speculate that mediators released by immune cells, most likely mast cells, in the submucosa trigger TRP sensitization and neuronal hypersensitivity. A small pilot study in 55 IBS patients assessing the effect of the Hrh1 antagonist ebastine for 12 wk revealed that ebastine improved global symptom relief in ~46% of patients with the maximal effect from 8 wk onward (128).

**TRPV4.** TRPV4 is regulated by serine/threonine phosphorylation in a similar manner to TRPV1. Both PKC and PKA, as downstream molecules of GPCR activation by inflammatory mediators such as histamine, 5-HT, bradykinin, PGE2, and proteases, can enhance the activation of TRPV4 via phosphorylation at specific residues, and the phosphorylation depends on the assembly of PKC and PKA (35). Besides phosphorylation, incubation of DRGs with histamine or serotonin triggered the translocation of TRPV4 to the membrane, an effect that can also contribute to neuronal potentiation (28).

As for TRPV1, the function of TRPV4 in visceral pain is strongly modulated by pro-inflammatory mediators that act on upstream GPCRs. For example, TRPV4 was found to be coexpressed with the protease receptor PAR-2 on nociceptive neurons (43, 100), and pretreatment of sensory DRG neurons with a PAR-2 agonist resulted in an enhanced TRPV4 activity, which was prevented by PKA and PKC inhibition (43). In vivo administration of subnociceptive doses of serotonin and histamine potentiated TRPV4-induced hypersensitivity in response to colorectal distention in mice, which was prevented by intravertebral injection of TRPV4 siRNA (28). Also, intraluminal administration of PAR-2 agonists resulted in an increased visceromotor response to colorectal distention, which was not observed in TRPV4 knockout mice (27, 100). In contrast, activation of PAR-4 significantly reduced the visceromotor response to colorectal distention in mice and inhibited PAR-2 agonist- and TRPV4 agonist-induced allodynia and hyperalgesia (10). These results are of particular interest as they demonstrate that activation of inhibitory GPCR receptor subunits can bind to inhibitory secondary signaling molecules, preventing and potentially reversing TRP potentiation.

**TRPA1.** Several studies on somatic pain already demonstrated that TRPA1 activation is also potentiated by GPCR activation. Indeed, both in vitro and in vivo experiments demonstrated that TRPA1 can be potentiated by bradykinin via PKA- and PLC-dependent pathways (97, 120). Also, activation
of PAR-2 by mast cell tryptase can trigger sensitization of TRPA1 involving PKA and PKC signaling, leading to somatic cold hyperalgesia in mice (30). In addition, TRPA1 sensitization by PAR-2 activation was observed in human embryonic kidney-293 (HEK-293) cells and DRG neurons, an effect that was mediated by PLC activation and phosphatidylinositol biphosphate (PIP2) (32). Degradation of PIP2 into diacylglycerol and inositol triphosphate leads to Ca2+ release from internal stores, and this intracellular Ca2+ mobilization may directly activate TRPA1 (139). Finally, inflammatory signals or acute activation of TRPA1 by mustard oil induces translocation of the TRPA1 channels to the membrane in sensory neurons which is PKA and PLC dependent (97).

In parallel, activation of colonic afferents with the inflammatory mediator bradykinin resulted in increased mechanosensitivity of these neurons, which was absent in TRPA1 knockout mice (19). Similarly, intracolonic administration of a PAR-2 agonist resulted in an increased visceromotor response to colorectal distention, which is abrogated by TRPA1 gene deletion (26). This finding was not confirmed by Brierley et al. (19), who did not find evidence to support an interaction of TRPA1 and PAR-2 in splanchic colonic afferents. Although the role of TRPA1 sensitization seems well established in somatic pain, its role in VHS in FGIDs remains to be elucidated.

**TRPM8.** Unlike TRPV1, TRPV4, and TRPA1 whose activation is enhanced by phosphorylation, modulation of TRPM8 by protein kinases appears to function as a negative regulator. Although there are no data available on TRPM8 in VHS, somatic pain studies showed that PKC and PKA activation initiates dephosphorylation of TRPM8 via phosphatase activation (16, 88). Various studies in murine DRG neurons show that treatment with pro-inflammatory mediators bradykinin and PGE2 led to a reduction in the amplitude of the TRPM8 response to cooling, resulting in a shift of the threshold to colder values. These effects were mediated by PKC and PKA, respectively (16, 71, 88). Another report confirmed the involvement of PKC in TRPM8 desensitization in HEK-293 cells (2). Others showed that a subset of sensory neurons coexpress TRPM8 ion channels and 5-HT1B receptors (5-HT1BR). The 5-HT1BR has previously been reported to exert an antinociceptive influence (42, 60). 5-HT1BRs signal through PLD and PKC, and subsequent activation of PKA, leading to phosphorylation of TRPM8 (103). Furthermore, intraperitoneal injection of a TRPV1 antagonist combined with a TRPA1 antagonist in a mouse model of experimental colitis results in a significant decrease of VHS compared with injection of the antagonists separately, suggesting a synergistic effect (115). Another study shows desensitization of TRPA1 in sensory neurons due to PIP2 depletion by activation of TRPV1 by capsaicin (6). Furthermore, cannabinoid-induced TRPV1 dephosphorylation in sensory neurons is absent if TRPA1 is knocked down, suggesting interaction between TRPA1 and TRPV1 (54). Of interest, activation of TRPM8 resulted in a decrease of agonist-evoked responses to TRPA1 and TRPV1 in colonic afferents, suggesting coexpression and cross talk between TRPM8, TRPV1, and TRPA1 (48). Taken together, these data suggest that cross-(de)sensitization of TRP channels can contribute to pain sensitivity in inflamed tissues and may serve as novel therapeutic targets.

**Cross Talk Between TRP Channels**

As various TRP channels are coexpressed on sensory neurons and often simultaneously upregulated or sensitized potentially downstream of various activated GPCRs in preclinical and clinical VHS, it has been proposed that TRP channels may also cross-sensitize each other. Indeed, 97% of TRPA1-positive sensory neurons coexpress TRPV1, while 30% of the TRPV1-positive neurons also express TRPA1, suggesting that these two TRP channels can interact (104). Several studies indeed showed that activation of TRPA1 can modulate TRPV1 activity. For example, activation of TRPA1 in DRG neurons results in sensitization of TRPV1, which involves activation of adenyl cyclase, cyclic adenosine monophosphate (cAMP), and subsequent activation of PKA, leading to phosphorylation of TRPV1 (103). Furthermore, cannabinoid-induced TRPV1 dephosphorylation in sensory neurons is absent if TRPA1 is knocked down, suggesting interaction between TRPA1 and TRPV1 (54). Of interest, activation of TRPM8 resulted in a decrease of agonist-evoked responses to TRPA1 and TRPV1 in colonic afferents, suggesting coexpression and cross talk between TRPM8, TRPV1, and TRPA1 (48). Taken together, these data suggest that cross-(de)sensitization of TRP channels can contribute to pain sensitivity in inflamed tissues and may serve as novel therapeutic targets.

**TRP Channels: Implications for Therapy**

Mounting evidence indicates that TRP channels are attractive targets for novel analgesics effective in a wide range of pathophysiological conditions, including VHS among many others, and numerous companies have initiated research tracks to identify TRP modulators. However, antagonizing TRP channels is challenging as they are often not only expressed by visceral sensory neurons but also by a multitude of tissues, including higher brain structures, nonsensory neurons, and nonneuronal cells, leading to severe side effects. Recently, a number of small-molecule TRPV1 antagonists have been advanced into clinical trials. The systemic use of TRPV1 antagonists revealed two major drawbacks, namely hyperthermia and impaired nociceptive and impaired nociceptive and thermosensation, leading to their withdrawal from clinical trials (33, 39, 40, 90). Some TRPV1 antagonists patented in recent years overcame the known undesirable side effects, making the development of TRPV1 antagonists much more promising (67, 98). Besides TRPV1 antagonists, prolonged intake of capsaicin also appears to desensitize afferent nerves against noxious stimuli. For example, ingestion of capsaicin capsules by healthy volunteers three times per day for 4 wk have been shown to decrease the pain response evoked by duodenal capsaicin administration and balloon distention (37). In line with these results, treatment of FD patients with capsaicin capsules for 5 wk resulted in a significant reduction of visceral pain (18). The challenge for an effective and safe therapy, however, will be to rather suppress...
the pathological contribution of TRPV1 to pain while preserving its physiological function.

TRPA1 may be a better candidate for therapeutic intervention as it is specifically expressed in a subclass of TRPV1-expressing nociceptors (104). TRPA1 antagonists do not have the same temperature regulation safety concerns as TRPV1 antagonists and may therefore be a more suitable target (89). Although the TRPA1 antagonist GRC17536 has shown efficacy in patients with painful diabetic neuropathy in Phase 2a proof-of-concept studies (89), studies on TRPA1 antagonism in VHS are completely lacking. To date there is also no clinical evidence available for TRPV4 antagonism, although new blockers have been developed and await to be assessed for their therapeutic efficacy and safety (116).

TRPM8 is often thought of as an ion channel giving rise to only nonpainful sensations, but more recent evidence suggests that TRPM8 channel agonists may have analgesic effects. Several double-blind placebo-controlled clinical trials indeed showed that ingestion of peppermint oil in IBS patients resulted in a significant decrease of abdominal pain perception while significantly improving quality of life in 75% of patients compared with 40% in patients treated with placebo (23, 62, 76). Moreover, a recent double-blind placebo-controlled clinical trial showed that ingestion of a novel formulation of peppermint oil with sustained release resulted in a 40% reduction of the total IBS symptom score (abdominal pain, bloating, urgency, etc.) after 4 wk treatment compared with 24.3% decrease in the placebo group (24). In addition herbal prepa-

---

**Fig. 1.** G protein-coupled receptor (GPCR) mediated transient receptor potential (TRP) channel sensitization contributing to visceral hypersensitivity. Activation of nociceptive Gαs-linked receptors, such as bradykinin receptor (BK₁), 5-hydroxytryptamine receptor (5HTR₁), histamine receptor (Hrh₂), and prostaglandin receptor (PGR), results in the production of cyclic adenosine monophosphate (cAMP) by adenylyl cyclase (AC). This leads to an increase of protein kinase C (PKC) activity resulting in TRP channel sensitization by phosphorylation. On the other hand, activation of nociceptive Gαq-linked receptors, such as bradykinin receptor (BK₂), protease-activated receptor 2 (PAR-2), 5-hydroxytryptamine receptor (5HTR₂), histamine receptor (Hrh₁), and prostaglandin receptor (PGR), leads to the production of diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP₃) by phospholipase C (PLC), resulting in protein kinase A (PKA) activation, which leads to TRP channel phosphorylation and sensitization. In parallel, Gαq activates phospholipase A2 (PLA₂), leading to the production of arachidonic acid (AA) and downstream polyunsaturated fatty acids (PUFAs) that can directly activate TRP channels. Activation and sensitization by phosphorylation of TRP channels contribute to aberrant pain perception and visceral hypersensitivity (VHS). Activation of Gαi-linked receptors by resolvins inhibits adenylyl cyclase, with subsequent downregulation of PKA antagonizing Gαs-mediated sensitization. PIP₂, phosphatidylinositol 4,5-bisphosphate; P, phosphate; Ca²⁺, calcium; Na⁺, sodium.

---

**AJP-Gastrointest Liver Physiol** • doi:10.1152/ajpgi.00401.2016 • www.ajpgi.org
rations containing peppermint successfully relieve FD-related symptoms such as epigastric/abdominal pain, bloating, and heartburn in 78% of the treated patients (94).

Altogether, even though there are some preliminary positive reports, the direct blockade of TRP channels often leads to severe side effects. It has been suggested that indirect action on the modulation of these channels may be a more promising approach. As described above, inflammatory mediators lower the threshold of several pronociceptive TRPs via activation of the corresponding GPCR. Hence, VHS may be counteracted by interfering with this process. In this line of thinking, we recently showed that Hrh1 antagonism prevents sensitization of TRPV1 on sensory neurons, resulting in significantly decreased abdominal pain in a proof-of-concept clinical trial (128). Since activation of PAR-2 has also been shown to sensitize TRPV1, TRPV4, and TRPA1 (30), blocking PAR-2 may also be a promising therapeutic approach; however, so far clinical evidence is lacking. Stimulation of GPCRs results in activation of several protein kinases that phosphorylate and sensitize TRP channels. Inhibition of the downstream pathways of GPCRs activation may represent an interesting alternative therapeutic approach for VHS. The success of kinase inhibitors in the treatment of cancer showcased their therapeutic potential (136). This success, coupled with a greater understanding of inflammatory signaling cascades, led to kinase inhibitors taking center stage in the pursuit for new anti-inflammatory agents for the treatment of (auto-)immune-mediated diseases (70). To date only a handful of kinase inhibitors have reached the stage of FDA approval, while others have had mixed results in clinical trials. It remains to be determined if protein kinases are good drug targets to treat FGIDs.

Recently, somatic pain studies have indicated that resolvins (Rv), a new class of compounds known for their anti-inflammatory properties, prevent activation of TRP channels including TRPA1, TRPV1, and TRPV4 (1, 13, 82, 132). Resolvins are endogenous lipid mediators produced by immune cells, including eosinophils and neutrophils, and drive the resolution phase of inflammation even at concentrations in the nanomolar range (99). Understandably, evidence is quickly growing for their pain-relieving potential too. To date, especially, RvE1, RvD1, and RvD2 have been studied for their analgesic properties. Increasing evidence shows that these resolvins potently interfere with TRP channel function, independent of their effect on the immune system (99). RvE1 and RvD1 were shown to normalize inflammatory pain by central and peripheral actions (132). Furthermore, resolvins inhibited acute pain evoked by intraplantar injection of TRPV1, TRPV4, and TRPA1 agonists. Also, in vitro, in DRG neurons and HEK cells, TRPV1, TRPV4, and TRPA1 signaling could be inhibited by RvD1, RvD2, and RvE1 (13, 82, 132). Besides TRP channel activation, it can be speculated that resolvins also prevent TRP channel sensitization. The mechanism by which resolvins inhibit TRP channel activation and sensitization is not entirely unraveled. It is proposed that resolvins activate inhibitory GPCR (Gα1) that antagonize the GPCR-mediated sensitization of TRP channels. Activation leads to inhibition of adenyl cyclase-dependent cAMP production and subsequent downregulation of PKA-mediated TRP sensitization (126). Therefore, this signaling mechanism is potentially a very interesting approach for resolving VHS in FGIDs, mediated by TRP channel sensitization.

Conclusions

Relief of chronic pain in FGIDs, including FD, IBS, and IBD in remission, is a largely unmet medical need. This review underscores the critical role of TRP ion channels in peripheral neuronal sensitization, generating and sustaining chronic pain by the increase in neuronal excitability in primary sensory neurons. TRP channels not only function as detectors of thermal, chemical, and mechanical stimuli but also serve as secondary transducers in which activation of various GPCRs by pro-inflammatory mediators triggers TRP sensitization leading to aberrant pain perception (Fig. 1). Therefore, TRP channels as well as the GPCRs and downstream signaling molecules are promising drug targets for the management of VHS as seen in several FGIDs. Since multiple inflammatory mediators have been identified that can individually result in TRP channel modulation via GPCR signaling, identifying the mediator signature in individual patients with VHS is key to predicting which treatment would be beneficial for relieving symptoms.

REFERENCES


DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the author(s).

AUTHOR CONTRIBUTIONS

D.B. prepared figures; D.B. drafted manuscript; D.B., G.E.B., K.T., and M.M.W. edited and revised manuscript; D.B., G.E.B., K.T., and M.M.W. approved final version of manuscript.

G. Boeckxstaens was funded by a governmental grant (Odysseus program, G-090507) of the Research Foundation-Flanders (FWO) and by a KU Leuven university grant (Global Opportunities for Associations GOA 14.011). M. Wouters was supported by a FWO postdoctoral fellowship (1248513N and 12C2113N, respectively). D. Baemans was supported by a FWO PhD fellowship (1127415N). This work was funded by FWO research grant G069910N (to G. Boeckxstaens and M. Wouters). K. Talavera was funded by a KU Leuven university grant (PF-TRPLe).

GRANTS

This work was funded by FWO research grant G·0699·10N (to G. Boeckxstaens and M. Wouters).
10. Barbara Bandell
13. Bang Brierley
21. Brierley
24. Balemans

11. Bautista
19. Brierley
20. Andersson

1111/j.1365-2982.2009.01310.x.
drome.
colonic nerves correlate with abdominal pain in irritable bowel syn-

attenuates activation of sensory transient receptor potential channels

activated by pungent compounds and bradykinin.
mouse DRG neurons.
Boeckxstaens GE.

activated receptor-4 (PAR4): a role as inhibitor of visceral pain and

hypersensitivity.

van Leuven F, Vennekens R, De Ridder D, Nilius B, Dewachter I, van


USA

Pungent products

The transient receptor potential channel TRPM8 is inhibited via

mediator of the noxious effects of mustard oil.
Voets T, Talavera K.


TRP4V1 elicits marked hyperthermia in humans.
Pain

perthermia elicited by TRPV1 blockade.

• doi:10.1152/ajpgi.00401.2016 • www.ajpgi.org

Gastroenterology

by 10.220.33.3 on September 30, 2017 http://ajpgi.physiology.org/ Downloaded from
TRP CHANNELS IN VISCERAL HYPERSENSITIVITY

Hosoya

53.

Halpin

45.

Jeske

54.

Gordillo-González

58.

Hammer

59.

Huang J, Zhang X, McNaughton PA.

47.

Hara Y, Wakamori M, Ishii M, Maeno E, Nishida M, Yoshida T,

46.

Hammer

59.

Huang J, Zhang X, McNaughton PA.

47.

Hara Y, Wakamori M, Ishii M, Maeno E, Nishida M, Yoshida T,

46.

Hammer

59.

Huang J, Zhang X, McNaughton PA.

47.

Hara Y, Wakamori M, Ishii M, Maeno E, Nishida M, Yoshida T,

46.

Hammer

59.

Huang J, Zhang X, McNaughton PA.

47.

Hara Y, Wakamori M, Ishii M, Maeno E, Nishida M, Yoshida T,

46.

Hammer

59.

Huang J, Zhang X, McNaughton PA.

47.

Hara Y, Wakamori M, Ishii M, Maeno E, Nishida M, Yoshida T,

46.

Hammer

59.

Huang J, Zhang X, McNaughton PA.

47.

Hara Y, Wakamori M, Ishii M, Maeno E, Nishida M, Yoshida T,

46.

Hammer

59.

Huang J, Zhang X, McNaughton PA.

47.

Hara Y, Wakamori M, Ishii M, Maeno E, Nishida M, Yoshida T,

46.

Hammer

59.

Huang J, Zhang X, McNaughton PA.

47.

Hara Y, Wakamori M, Ishii M, Maeno E, Nishida M, Yoshida T,

46.

Hammer

59.

Huang J, Zhang X, McNaughton PA.

47.

Hara Y, Wakamori M, Ishii M, Maeno E, Nishida M, Yoshida T,

46.

Hammer

59.

Huang J, Zhang X, McNaughton PA.

47.

Hara Y, Wakamori M, Ishii M, Maeno E, Nishida M, Yoshida T,

46.

Hammer

59.

Huang J, Zhang X, McNaughton PA.

47.

Hara Y, Wakamori M, Ishii M, Maeno E, Nishida M, Yoshida T,

46.

Hammer

59.

Huang J, Zhang X, McNaughton PA.

47.

Hara Y, Wakamori M, Ishii M, Maeno E, Nishida M, Yoshida T,

46.
TRP CHANNELS IN VISCERAL HYPERSENSITIVITY


125. Wehrhahn J, Kraft R, Harteneck C, Haußchild S. Transient receptor potential melastatin 2 is required for lipopolysaccharide-induced cyto-